Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer
Open Access
- 28 February 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (10) , 11870-11882
Abstract
Palmitoyl-protein thioesterase 1 (PPT1) is an understudied enzyme that is gaining attention due to its role in the depalmitoylation of several proteins involved in neurodegenerative diseases and cancer. PPT1 is overexpressed in several cancers, specifically cholangiocarcinoma and esophageal cancers. Inhibitors of PPT1 lead to cell death and have been shown to enhance the killing of tumor cells alongside known chemotherapeutics. PPT1 is hence a viable target for anticancer drug development. Furthermore, mutations in PPT1 cause a lysosomal storage disorder called infantile neuronal ceroid lipofuscinosis (CLN1 disease). Molecules that can inhibit, stabilize, or modulate the activity of this target are needed to address these diseases. We used PPT1 enzymatic assays to identify molecules that were subsequently tested by using differential scanning fluorimetry and microscale thermophoresis. Selected compounds were also tested in neuroblastoma cell lines. The resulting PPT1 screening data was used for building machine learning models to help select additional compounds for testing. We discovered two of the most potent PPT1 inhibitors reported to date, orlistat (IC50 178.8 nM) and palmostatin B (IC50 11.8 nM). When tested in HepG2 cells, it was found that these molecules had decreased activity, indicating that they were likely not penetrating the cells. The combination of in vitro enzymatic and biophysical assays enabled the identification of several molecules that can bind or inhibit PPT1 and may aid in the discovery of modulators or chaperones. The molecules identified could be used as a starting point for further optimization as treatments for other potential therapeutic applications outside CLN1 disease, such as cancer and neurological diseases.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (3R43NS107079-01S1, 5R44NS107079-03, 1R43NS107079-01, 3R43NS107079-01S2)
- National Center for Complementary and Integrative Health (1R43AT010585-01)
- National Institute of General Medical Sciences (R44GM122196-02A1)
This publication has 75 references indexed in Scilit:
- Protein palmitoylation in cancer: molecular functions and therapeutic potentialMolecular Oncology, 2022
- Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus diseaseAntiviral Research, 2020
- Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sortingThe EMBO Journal, 2014
- Identification of Acyl Protein Thioesterases 1 and 2 as the Cellular Targets of the Ras‐Signaling Modulators Palmostatin B and MAngewandte Chemie International Edition, 2011
- Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Molecular Medicine, 2009
- Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cellsJournal of Neuroscience Research, 2000
- A Rapid Fluorogenic Palmitoyl-Protein Thioesterase Assay: Pre- and Postnatal Diagnosis of INCLMolecular Genetics and Metabolism, 1999
- Lysosomal Biogenesis in Lysosomal Storage DisordersExperimental Cell Research, 1997
- Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis.The EMBO Journal, 1996
- Comparison of the predicted and observed secondary structure of T4 phage lysozymeBiochimica et Biophysica Acta (BBA) - Protein Structure, 1975